Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta‐Analysis

Optimizing Statins and Ezetimibe in Guideline-Focused Management

(2018) Aref A. Bin Abdulhak et al.   CARDIOLOGY CLINICS

Impact of statin-ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease — Sub-analysis of PRECISE-IVUS trial

(2018) Koichiro Fujisue et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial

(2017) Nobuhisa Hagiwara et al.   EUROPEAN HEART JOURNAL

2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

(2017) Donald M. Lloyd-Jones et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function

(2017) John W. Stanifer et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

2017 Taiwan lipid guidelines for high risk patients

(2017) Yi-Heng Li et al.   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

Krótkoterminowy wpływ terapii atorwastatyną i ezetimibem w porównaniu z monoterapią atorwastatyną na stan kliniczny chorych z ostrym zespołem wieńcowym w zależności od płci

(2017) Lasha Japaridze et al.   Kardiologia Polska

Dyslipidemia in patients with chronic kidney disease

(2016) Matthew R. Hager et al.   REVIEWS IN ENDOCRINE & METABOLIC DISORDERS

Statins and Cardiovascular Primary Prevention in CKD: A Meta-Analysis

(2015) R. W. Major et al.   Clinical Journal of the American Society of Nephrology

High-intensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis

(2015) Y.-L. Yan et al.   BMJ Open

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation

(2015) L. Shamseer et al.   BMJ-British Medical Journal

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation

(2015) L. Shamseer et al.   BMJ-British Medical Journal

Lipid Management in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2013 Clinical Practice Guideline

(2014) Marcello Tonelli et al.   ANNALS OF INTERNAL MEDICINE

Chronic kidney disease and cardiovascular complications

(2014) Luca Di Lullo et al.   HEART FAILURE REVIEWS

Lipid-Lowering Therapy in Persons With Chronic Kidney Disease

(2013) Ashish Upadhyay et al.   ANNALS OF INTERNAL MEDICINE

Benefits and Harms of Statin Therapy for Persons With Chronic Kidney Disease

(2013) Suetonia C. Palmer et al.   ANNALS OF INTERNAL MEDICINE

Medical Management of Stable Coronary Atherosclerosis

(2013) P. Pellicori et al.   Current Atherosclerosis Reports

Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward

(2013) Adeera Levin et al.   KIDNEY INTERNATIONAL

GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables

(2011) Gordon Guyatt et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

(2011) Colin Baigent et al.   LANCET

Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease

(2010) SHARP Collaborative Group   AMERICAN HEART JOURNAL

Early recognition and prevention of chronic kidney disease

(2010) Matthew T James et al.   LANCET

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner

(2009) Tsukasa Nakamura et al.   PHARMACOLOGICAL RESEARCH

SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study

(2008)   NEW ENGLAND JOURNAL OF MEDICINE